HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Platelet endothelial cell adhesion molecule-1 inhibits platelet response to thrombin and von Willebrand factor by regulating the internalization of glycoprotein Ib via AKT/glycogen synthase kinase-3/dynamin and integrin αIIbβ3.

AbstractOBJECTIVE:
Platelet endothelial cell adhesion molecule-1 (PECAM-1) regulates platelet response to multiple agonists. How this immunoreceptor tyrosine-based inhibitory motif-containing receptor inhibits G protein-coupled receptor-mediated thrombin-induced activation of platelets is unknown.
APPROACH AND RESULTS:
Here, we show that the activation of PECAM-1 inhibits fibrinogen binding to integrin αIIbβ3 and P-selectin surface expression in response to thrombin (0.1-3 U/mL) but not thrombin receptor-activating peptides SFLLRN (3×10(-7)-1×10(-5) mol/L) and GYPGQV (3×10(-6)-1×10(-4) mol/L). We hypothesized a role for PECAM-1 in reducing the tethering of thrombin to glycoprotein Ibα (GPIbα) on the platelet surface. We show that PECAM-1 signaling regulates the binding of fluorescein isothiocyanate-labeled thrombin to the platelet surface and reduces the levels of cell surface GPIbα by promoting its internalization, while concomitantly reducing the binding of platelets to von Willebrand factor under flow in vitro. PECAM-1-mediated internalization of GPIbα was reduced in the presence of both EGTA and cytochalasin D or latrunculin, but not either individually, and was reduced in mice in which tyrosines 747 and 759 of the cytoplasmic tail of β3 integrin were mutated to phenylalanine. Furthermore, PECAM-1 cross-linking led to a significant reduction in the phosphorylation of glycogen synthase kinase-3β Ser(9), but interestingly an increase in glycogen synthase kinase-3α pSer(21). PECAM-1-mediated internalization of GPIbα was reduced by inhibitors of dynamin (Dynasore) and glycogen synthase kinase-3 (CHIR99021), an effect that was enhanced in the presence of EGTA.
CONCLUSIONS:
PECAM-1 mediates internalization of GPIbα in platelets through dual AKT/protein kinase B/glycogen synthase kinase-3/dynamin-dependent and αIIbβ3-dependent mechanisms. These findings expand our understanding of how PECAM-1 regulates nonimmunoreceptor signaling pathways and helps to explains how PECAM-1 regulates thrombosis.
AuthorsChris I Jones, Tanya Sage, Leonardo A Moraes, Sakthivel Vaiyapuri, Umara Hussain, Katherine L Tucker, Natasha E Barrett, Jonathan M Gibbins
JournalArteriosclerosis, thrombosis, and vascular biology (Arterioscler Thromb Vasc Biol) Vol. 34 Issue 9 Pg. 1968-76 (Sep 2014) ISSN: 1524-4636 [Electronic] United States
PMID24969778 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Copyright© 2014 American Heart Association, Inc.
Chemical References
  • Bridged Bicyclo Compounds, Heterocyclic
  • Platelet Endothelial Cell Adhesion Molecule-1
  • Platelet Glycoprotein GPIIb-IIIa Complex
  • Platelet Glycoprotein GPIb-IX Complex
  • Thiazolidines
  • von Willebrand Factor
  • Cytochalasin D
  • Proto-Oncogene Proteins c-akt
  • Glycogen Synthase Kinase 3
  • Thrombin
  • Dynamins
  • latrunculin A
  • Calcium
Topics
  • Animals
  • Bridged Bicyclo Compounds, Heterocyclic (pharmacology)
  • Calcium (metabolism)
  • Cytochalasin D (pharmacology)
  • Cytoskeleton (drug effects, ultrastructure)
  • Dynamins (physiology)
  • Glycogen Synthase Kinase 3 (physiology)
  • Humans
  • Mice
  • Mice, Knockout
  • Platelet Activation (drug effects, physiology)
  • Platelet Endothelial Cell Adhesion Molecule-1 (genetics, pharmacology, physiology)
  • Platelet Glycoprotein GPIIb-IIIa Complex (physiology)
  • Platelet Glycoprotein GPIb-IX Complex (metabolism)
  • Protein Structure, Tertiary
  • Protein Transport
  • Proto-Oncogene Proteins c-akt (physiology)
  • Signal Transduction (drug effects, physiology)
  • Thiazolidines (pharmacology)
  • Thrombin (pharmacology)
  • von Willebrand Factor (pharmacology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: